Immunotherapy is a powerful technique where immune cells are modified to improve cytotoxicity against cancerous cells to treat cancers that do not respond to surgery, chemotherapy, or radiotherapy. Expressing chimeric antigen receptor (CAR) in immune cells, typically T lymphocytes, is a practical modification that drives an immune response against cancerous tissue. CAR-T efficacy is suboptimal in solid tumors due to the tumor microenvironment (TME) that limits T lymphocyte cytotoxicity. In this study, we demonstrate that neutrophils differentiated from human pluripotent stem cells modified with AAVS1-inserted CAR constructs showed a robust cytotoxic effect against prostate-specific membrane antigen (PSMA) expressing LNCaP cells as a model for prostate cancer in vitro . Our results suggest that engineered CAR can significantly enhance the neutrophil anti-tumor effect, providing a new avenue in treating prostate cancers.
Keyphrases
- pluripotent stem cells
- prostate cancer
- induced apoptosis
- radical prostatectomy
- immune response
- cell cycle arrest
- minimally invasive
- early stage
- endothelial cells
- locally advanced
- pet ct
- squamous cell carcinoma
- radiation therapy
- oxidative stress
- young adults
- pi k akt
- endoplasmic reticulum stress
- cell death
- pet imaging
- computed tomography
- signaling pathway
- inflammatory response
- toll like receptor
- childhood cancer